Publication
A plasma derived hypoxia signature predicts benefit from hypoxia-modifying radiotherapy and reveals dynamic humoral immune modulation in bladder cancer.
C Guerrero Quiles, H Abumanhal-Masarweh, J G Abalos, T Lodhi, D Sanchez-Martinez, K Reeves, Nicholas D James, Emma Hall, Robert A Huddart, Nuria Porta, P Hoskin, L V Biolatti, M Hadjidemetriou, C M West, A Choudhury
- Source
- PubMed
- Retrieved
- Sep 29, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260929-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
INTRODUCTION: Hypoxia is a hallmark of solid tumours and drives radioresistance, yet no hypoxia biomarkers are used clinically. We explored nanoproteomics to identify a plasma protein signature for longitudinal non-invasive hypoxia monitoring. METHODS: Twenty-three bladder cancer patients (T2-T3b)…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Bladder Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available